TMBBY yields 9.67% · JNJ yields 2.13%● Live data
📍 TMBBY pulled ahead of the other in Year 1
Combined, TMBBY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TMBBY + JNJ for your $10,000?
TMBThanachart Bank Public Company Limited, together with its subsidiaries, provides various commercial banking products and services to individuals, small and medium sized enterprises (SME), and corporate customers primarily in Thailand. It operates through Commercial Banking and Retail Banking segments. The company offers basic, current, cash concentration, corporate liquidity, term and foreign currency deposit, multi-currency, and savings accounts; working capital, personal, home, auto, credit card, long-term, unsecured, and other loans, as well as special funding programs for SME, letter of guarantee, and supply chain solutions; and debit, credit, and corporate cards. It also provides trade finance, foreign exchange and currency, financial management, hire purchase, finance leasing, bancassurance, and mutual funds, asset management, insurance brokerage, investment banking and advisory, import and export trading, payment, collection, liquidity management, capital market risk management, agency, and other financial services. In addition, the company offers wealth banking, mobile and Internet banking services; mutual funds; and business and properties protection, life and health, personal accident, motor, and travel insurance products. As of December 31, 2021, it operated 636 branches; 3,043 ATMs; and 598 CDMs. The company was formerly known as TMB Bank Public Company Limited and changed its name to TMBThanachart Bank Public Company Limited in May 2021. TMBThanachart Bank Public Company Limited was founded in 1957 and is headquartered in Bangkok, Thailand.
Full TMBBY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.